Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | MAT2A | P31153 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.33 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19335054 | 0.82 | KDM4C (0.47) | KDM4CKMT2APOLBCYP1A2CYP2D6 | |
| SCHEMBL14738128 | 0.78 | KDM4C (0.43) | KDM4CKMT2APOLBCYP1A2KDM4E | |
| SCHEMBL17610157 | 0.77 | KDM4C (0.46) | KDM4CKMT2APOLBGRM2HTR2A | |
| SCHEMBL17610149 | 0.75 | KDM4C (0.38) | KDM4CPOLBCYP1A2CYP2D6MAT2A | |
| SCHEMBL15802435 | 0.75 | KDM4C (0.47) | KDM4CKMT2APOLBGRM2HTR2A | |
| SCHEMBL15792715 | 0.73 | KDM4C (0.39) | KDM4CGRM2HTR2AHTR2CSLC6A4 | |
| SCHEMBL21204917 | 0.71 | KMO (0.56) | KDM4CKMT2APOLBGRM2HTR2A | |
| SCHEMBL17610137 | 0.69 | POLB (0.41) | KDM4CKMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL19597220 | 0.69 | KDM4C (0.47) | KDM4CKMT2APOLBGRM2HTR2A | |
| SCHEMBL15792036 | 0.69 | KDM4C (0.41) | KDM4CCYP1A2CYP2D6HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194387-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3194387-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10231957-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10231957-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180271843-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-10016401-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016401-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016401-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9758517-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758517-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758517-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| EP-3194387-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2016044138-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044138-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016401-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5A | KDM4C 12/4885KMT2A 42/4885POLB 662/4885 |
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM4C 12/4885KMT2A 42/4885POLB 662/4885 |
| US-20180271843-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM4C 12/4885KMT2A 42/4885POLB 662/4885 |
| US-10231957-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5A | KDM4C 12/4885KMT2A 42/4885POLB 662/4885 |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM4C 12/4885KMT2A 42/4885POLB 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.